$15.36
5.54% yesterday
NYSE, Nov 15, 09:49 pm CET
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Zymeworks Inc. Stock price

$15.39
+1.47 10.52% 1M
+6.24 68.20% 6M
+5.00 48.12% YTD
+7.68 99.61% 1Y
-4.15 21.24% 3Y
-20.75 57.42% 5Y
+2.39 18.38% 10Y
NYSE, Closing price Fri, Nov 15 2024
-0.87 5.35%
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Key metrics

Market capitalization $1.07b
Enterprise Value $791.86m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.73
P/S ratio (TTM) P/S ratio 17.18
P/B ratio (TTM) P/B ratio 2.94
Revenue growth (TTM) Revenue growth -86.52%
Revenue (TTM) Revenue $62.20m
EBIT (operating result TTM) EBIT $-121.03m
Free Cash Flow (TTM) Free Cash Flow $-54.68m
Cash position $297.20m
EPS (TTM) EPS $-1.51
P/E forward negative
P/S forward 11.34
EV/Sales forward 8.56
Short interest 8.41%
Show more

Is Zymeworks Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Zymeworks Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Zymeworks Inc. forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Zymeworks Inc. forecast:

Buy
50%
Hold
50%

Financial data from Zymeworks Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
62 62
87% 87%
100%
- Direct Costs 11 11
33% 33%
17%
51 51
88% 88%
83%
- Selling and Administrative Expenses 38 38
28% 28%
62%
- Research and Development Expense 123 123
28% 28%
198%
-110 -110
150% 150%
-177%
- Depreciation and Amortization 11 11
33% 33%
17%
EBIT (Operating Income) EBIT -121 -121
159% 159%
-195%
Net Profit -114 -114
155% 155%
-183%

In millions USD.

Don't miss a Thing! We will send you all news about Zymeworks Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zymeworks Inc. Stock News

Neutral
GlobeNewsWire
11 days ago
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers
Positive
Seeking Alpha
12 days ago
The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus tislelizumab for treatment of patients with 1st-line GEA is expected in Q2 of 2025. Zanidatamab is being developed in collaboration ...
Neutral
Seeking Alpha
15 days ago
Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief executive Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubara...
More Zymeworks Inc. News

Company Profile

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Ken Galbraith
Employees 277
Founded 2003
Website www.zymeworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today